Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
The Prostate · 2025-09 · 85 (12) · 1151-1154
DOI: 10.1002/pros.24923 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 08.06.2025. Verfasst von András Horváth und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Benzamides, Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Androstenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.
Methods
A large, country‐wide health insurance database (2013‐2023) was assessed for the OS comparison between abiraterone and enzalutamide.
Results
Overall, 3497 patients were identified with first‐ ( n = 2215) or second‐line ( n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide‐treated patients had longer OS both in the first‐ (HR:0.84; 95%CI:0.74‐0.96; p = 0.008) and the second‐line setting (HR:0.88; 95%CI:0.78‐0.99; p = 0.043), respectively.
Conclusions
This health insurance‐registry‐based study suggests that, in the real‐world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Semmelweis University, Budapest, Hungary.
- MedicalScan Ltd., Budapest, Hungary.
- Department of Urology, University of Duisburg-Essen, Essen, Germany.
- Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
- Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.
ORCID-Profile: Pawel Rajwa
Zitieren
APA
Horváth, A., Blasszauer, C., Komka, I., Reibl, D., Hadaschik, B., Fazekas, T., Rajwa, P., Soós, À., Valikovics, A., Nyirády, P., & Szarvas, T. (2025). Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer. The Prostate, 85(12), 1151-1154. https://doi.org/10.1002/pros.24923
Vancouver
Horváth A, Blasszauer C, Komka I, Reibl D, Hadaschik B, Fazekas T, et al. Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer. The Prostate. 2025;85(12):1151-1154. doi:10.1002/pros.24923
BibTeX
@article{Horvth2025,
author = {Horváth, András and Blasszauer, Celia and Komka, Ida and Reibl, Dániel and Hadaschik, Boris and Fazekas, Tamás and Rajwa, Pawel and Soós, Àron and Valikovics, Anikó and Nyirády, Péter and Szarvas, Tibor},
title = {Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer},
journal = {The Prostate},
year = {2025},
volume = {85},
number = {12},
pages = {1151--1154},
doi = {10.1002/pros.24923}
}
EUVIMED